Journal: Cell systems

Article Title: Quantifying drug combination synergy along potency and efficacy axes.

doi: 10.1016/j.cels.2019.01.003

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: Primaquine Diphosphate , SelleckChem , S4237.

Techniques: Virus, Recombinant, Sample Prep, Reverse Transcription, SYBR Green Assay, Expressing, Derivative Assay, Plasmid Preparation, Software

Journal: Orphanet Journal of Rare Diseases

Article Title: Pharmaceutical compounding of orphan active ingredients in Belgium: how community and hospital pharmacists can address the needs of patients with rare diseases

doi: 10.1186/s13023-019-1154-x

Figure Lengend Snippet: Overview of the OAIs, excipients and packaging used in the compounded formulations

Article Snippet: Primaquine phosphate , BOC Sciences Creative Dynamics, Shirley, United States.

Techniques: Capsules

Journal: Orphanet Journal of Rare Diseases

Article Title: Pharmaceutical compounding of orphan active ingredients in Belgium: how community and hospital pharmacists can address the needs of patients with rare diseases

doi: 10.1186/s13023-019-1154-x

Figure Lengend Snippet: Priority list of the OAIs

Article Snippet: Primaquine phosphate , BOC Sciences Creative Dynamics, Shirley, United States.

Techniques:

Journal: Orphanet Journal of Rare Diseases

Article Title: Pharmaceutical compounding of orphan active ingredients in Belgium: how community and hospital pharmacists can address the needs of patients with rare diseases

doi: 10.1186/s13023-019-1154-x

Figure Lengend Snippet: Overview of the OAIs included in current study

Article Snippet: Primaquine phosphate , BOC Sciences Creative Dynamics, Shirley, United States.

Techniques: Concentration Assay, Capsules

Journal: Orphanet Journal of Rare Diseases

Article Title: Pharmaceutical compounding of orphan active ingredients in Belgium: how community and hospital pharmacists can address the needs of patients with rare diseases

doi: 10.1186/s13023-019-1154-x

Figure Lengend Snippet: Overview of the applied analytical methods

Article Snippet: Primaquine phosphate , BOC Sciences Creative Dynamics, Shirley, United States.

Techniques: Injection

Journal: Orphanet Journal of Rare Diseases

Article Title: Pharmaceutical compounding of orphan active ingredients in Belgium: how community and hospital pharmacists can address the needs of patients with rare diseases

doi: 10.1186/s13023-019-1154-x

Figure Lengend Snippet: Overview of the shelf life and assay stability results

Article Snippet: Primaquine phosphate , BOC Sciences Creative Dynamics, Shirley, United States.

Techniques: Capsules

Journal: Breast Cancer Research and Treatment

Article Title: Endosomal recycling inhibitors downregulate estrogen receptor-alpha and synergise with endocrine therapies

doi: 10.1007/s10549-023-07225-2

Figure Lengend Snippet: IC50 values for the ER-α antagonist tamoxifen, endosomal recycling inhibitors (primaquine and monensin) and their combinations in the indicated breast cancer cell lines

Article Snippet: Primaquine, lapatinib, enzalutamide, and MTT were purchased from Carbosynth, UK.

Techniques:

Journal: The Journal of General Physiology

Article Title: Rapid resensitization of ASIC2a is conferred by three amino acid residues in the N terminus

doi: 10.1085/jgp.201812224

Figure Lengend Snippet: The prolonged desensitization of the ASIC2a mutants is not due to an internalization of the ion channels in response to extracellular protons. (A) Currents elicited by three consecutive applications of pH 4.0 for 20 s in HEK293T cells expressing either Mut2 (upper) or Mut3 (lower) in the absence (blue) or presence (red) of 50 µM primaquine, begun 1 h before the recordings. (B) Peak current densities in cells expressing either Mut2 (upper) or Mut3 (lower) were normalized to those evoked by the initial acidic stimulus in the absence (blue) or presence (red) of 50 µM primaquine. n = 5 for each group. Acidic stimuli were delivered by switching the bath solution from pH 7.4 to pH 4.0 at 2-min intervals. (C and D) Western blotting showing the amounts of GFP-tagged Mut2 and Mut3 in the plasma membrane (PM) and total cell lysate (Total) following application of pH 7.4 versus pH 4.0. E-cadherin and GAPDH are markers used to normalize the amounts of Mut2 and Mut3 in the plasma membrane and total cell lysate, respectively. n = 3 for each group. n.s. not significant; Mann–Whitney U test.

Article Snippet: Transfected HEK293 cells were pretreated for 1 h with primaquine (50 μM; LKT Laboratories), and the bath solution was continuously perfused with primaquine over the course of the recording.

Techniques: Expressing, Western Blot, Clinical Proteomics, Membrane, MANN-WHITNEY

Journal: Antimicrobial Agents and Chemotherapy

Article Title: Effect of Fluorescent Dyes on In Vitro -Differentiated, Late-Stage Plasmodium falciparum Gametocytes

doi: 10.1128/AAC.03772-14

Figure Lengend Snippet: In vitro activities of standard antimalarial drugs and dyes against stage V gametocytes of the P. falciparum 3D7 laboratory strain and clinical isolates after 48 h of incubation a

Article Snippet: Artesunate and primaquine were from Santa Cruz Biotechnology. fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window FIG 2 caption a7 Chemical structures of the tested synthetic dyes.

Techniques: In Vitro, Incubation

Journal: Antimicrobial Agents and Chemotherapy

Article Title: Effect of Fluorescent Dyes on In Vitro -Differentiated, Late-Stage Plasmodium falciparum Gametocytes

doi: 10.1128/AAC.03772-14

Figure Lengend Snippet: In vitro activities of compounds against mature gametocytes of 3D7 and clinical isolates of P. falciparum after 24 h or 48 h of incubation a

Article Snippet: Artesunate and primaquine were from Santa Cruz Biotechnology. fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window FIG 2 caption a7 Chemical structures of the tested synthetic dyes.

Techniques: In Vitro, Incubation

Journal: Malaria Research and Treatment

Article Title: Sustained Release Formulation of Primaquine for Prevention of Relapse of Plasmodium vivax Malaria: A Randomized, Double-Blind, Comparative, Multicentric Study

doi: 10.1155/2015/579864

Figure Lengend Snippet: Disposition of study participants. PT: primaquine therapy, CT: chloroquine therapy, and MP: malarial parasite.

Article Snippet: The concept of developing primaquine SR 15 mg (manufactured by Ipca Labortories Ltd., India) and primaquine SR 30 mg (manufactured by Ipca Labortories Ltd., India) formulations was based on maintaining adequate therapeutic concentration over 24 hours and reducing the treatment duration from 14 days to seven days for better patient compliance.

Techniques:

Journal: Malaria Research and Treatment

Article Title: Sustained Release Formulation of Primaquine for Prevention of Relapse of Plasmodium vivax Malaria: A Randomized, Double-Blind, Comparative, Multicentric Study

doi: 10.1155/2015/579864

Figure Lengend Snippet: Kaplan-Meier estimates of cumulative risk of relapse. P 15 mg: conventional primaquine 15 mg, PSR 15 mg: primaquine sustained release 15 mg, and PSR 30 mg: primaquine sustained release 30 mg. Numbers written over the line are patients still undergoing follow-up. Differences in cumulative risk of relapse are statistically insignificant; p = 0.16 for test of equality over strata using Log rank test.

Article Snippet: The concept of developing primaquine SR 15 mg (manufactured by Ipca Labortories Ltd., India) and primaquine SR 30 mg (manufactured by Ipca Labortories Ltd., India) formulations was based on maintaining adequate therapeutic concentration over 24 hours and reducing the treatment duration from 14 days to seven days for better patient compliance.

Techniques:

Journal: Malaria Research and Treatment

Article Title: Sustained Release Formulation of Primaquine for Prevention of Relapse of Plasmodium vivax Malaria: A Randomized, Double-Blind, Comparative, Multicentric Study

doi: 10.1155/2015/579864

Figure Lengend Snippet: Numbers of AEs reported during chloroquine therapy and primaquine therapy.

Article Snippet: The concept of developing primaquine SR 15 mg (manufactured by Ipca Labortories Ltd., India) and primaquine SR 30 mg (manufactured by Ipca Labortories Ltd., India) formulations was based on maintaining adequate therapeutic concentration over 24 hours and reducing the treatment duration from 14 days to seven days for better patient compliance.

Techniques: